INOVIO PHARMACEUTICALS, INC. — Director's Dealing 2021

Mar 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INOVIO PHARMACEUTICALS, INC. (INO)
CIK: 0001055726
Period of Report: 2021-03-11

Reporting Person: Kim Jong Joseph (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-11	Common Stock	M	139387	—	Acquired	1303203	Direct
2021-03-11	Common Stock	F	74545	$10.57	Disposed	1228658	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-11	Restricted Stock Unit	$	M	139387	Disposed		Common Stock (139387.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	816527	Indirect
Common Stock	33563	Indirect
Common Stock	33775	Indirect
Common Stock	5975	Indirect
Common Stock	33533	Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares will vest on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.